Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of GQ1001 and Pyrotinib in HER2 Positive Metastatic Breast Cancer Patients Who Had Failed Previous Anti-HER2 Treatment（GRACE）

NCT05575804 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05575804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05575804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of GQ1001 and Pyrotinib in HER2 Positive Metastatic Breast Cancer Patients Who Had Failed Previous Anti-HER2 Treatment（GRACE）
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 1, 2022
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/ metastatic her-2 positive breast cancer